A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-12-29
Adverse events
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 4); relationship: not assessed
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2023-02-12 (study day 36); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-01 (study day 53); relationship: N; serious criteria: hospitalization
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-04-24 (study day 107); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-08 (study day 152); relationship: N
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 173); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-29 (study day 265); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-20 (study day 347); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-13 (study day 371); relationship: not assessed
Data queries
No data queries.